AstraZeneca to build $475M small molecule drug plant in Wuxi, China

AstraZeneca has signed an agreement to invest $475 million to build a new small molecule drug manufacturing facility in Wuxi, Jiangsu, China. The plant will produce specific small molecule drugs for both Chinese and global markets.

“我们很高兴此次在无锡投资4.75亿美元新建小分子药物工厂，无锡是我们在华发展30多年的首站。”astrazeneca.com

• 1 source
• astrazeneca.com阿斯利康投资4.75亿美元在华新建小分子药物工厂Mar 1, 2024

Summarized from public sources; check the original articles before acting on it.